Mallinckrodt Inc. and Zogenix, Inc. Announce Exclusive Co-Promotion Arrangement on SUMAVEL® DosePro®

Published: Jun 07, 2012

HAZELWOOD, Mo.--(BUSINESS WIRE)--Mallinckrodt LLC, the Pharmaceuticals business of Covidien (NYSE: COV), today announced that it has entered into a co-promotion agreement with Zogenix Inc. (NASDAQ: ZGNX) for SUMAVEL®DosePro® (sumatriptan injection), a prescription medicine given with a needle-free delivery system to treat adults who have been diagnosed with acute migraine or cluster headaches.

Back to news